PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year Ending	TTM	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020	Apr 30, 2019	2018 - 2008
Net Income	-1.14	-4.32	-4.24	-3.55	-3.83	-4.07	Upgrade
Share-Based Compensation	0.67	0.65	0.11	0.44	1.22	1.02	Upgrade
Other Operating Activities	-1.64	-0.13	0.01	-0.22	0.27	0.17	Upgrade
Operating Cash Flow	-2.11	-3.79	-4.12	-3.33	-2.34	-2.88	Upgrade
Change in Investments	-5	0	0	0	0	0	Upgrade
Investing Cash Flow	-5	0	0	0	0	0	Upgrade
Share Issuance / Repurchase	-31.33	-13.56	87.36	4.7	2.66	2.34	Upgrade
Debt Issued / Paid	0	0	-0.05	-0.06	0.06	0	Upgrade
Other Financing Activities	27.01	-	-	-	-	-	Upgrade
Financing Cash Flow	-4.32	-13.56	87.31	4.64	2.73	2.34	Upgrade
Exchange Rate Effect	-0.01	-0.01	0	0	-0.01	-0.01	Upgrade
Net Cash Flow	-11.43	-17.36	83.2	1.31	0.38	-0.54	Upgrade
Free Cash Flow	-2.11	-3.79	-4.12	-3.33	-2.34	-2.88	Upgrade
Free Cash Flow Per Share	-0.24	-0.20	-0.27	-2.30	-2.59	-3.92	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).